Oncology Today with Dr Neil Love Ovarian Cancer — Year in Review Series on Relevant New Datasets and Advances
Mar 7, 2026
Dr Kathleen N Moore, medical oncologist focused on ovarian cancer trials, and Prof Nicoletta Colombo, gynecologic oncologist and researcher, review therapy selection and sequencing. They discuss redefining platinum ineligibility, practical options outside trials, FR-alpha and CDH6 ADCs, pembrolizumab plus weekly paclitaxel, relacorilant combos, PARP frontline strategies and T-DXd benefits and ILD precautions.
AI Snips
Chapters
Transcript
Episode notes
Multiple FR‑Alpha ADCs Share A Sequencing Problem
- Multiple FR-alpha ADCs (TOP1 payload) show ~50% response in platinum-ineligible/resistant disease.
- Concern: many share the same payload, complicating sequencing and reuse after one ADC.
TOP1 ADCs Can Work After Mirvetuximab
- Kathleen Moore notes TOP1-conjugated ADCs have activity after mirvetuximab in phase 1 experience.
- She enrolled post-mirvetuximab patients on TOP1 ADC trials and reports they respond.
CDH6 ADC Shows Broad Activity Independent Of Expression
- Relatlimab (CDH6? actually relutocatag) is a CDH6-targeting ADC with a TOP1 payload showing high responses across CDH6 expression levels.
- Phase III will enroll all comers without biomarker selection to compare against single-agent chemo.